FLORENCE, S.C., Dec. 18, 2015 (GLOBE NEWSWIRE) -- DeGen Medical has received clearance from the FDA for our cervical interbody fusion device - Latitude-C™ Cervical Interbody Spacer System. Latitude-C™ Cervical Interbody Spacer offers the surgeon a wide variety of materials based on patient needs – PEEK-OPTIMA®, Porous Titanium with PEEK, PEEK-OPTIMA® HA Enhanced, Titanium and Carbon fiber-reinforced (CFR) PEEK-OPTIMA®.
|
|||||
The Latitude-C™ Cervical Interbody Spacer is unique, patent pending design considers the uncinate process of the cervical vertebra. The lateral angles of the Latitude-C™ cervical spacer device are unique to match individual patient anatomy and different angles allow for perfect fit at every fusion level.
"The Latitude-C™ graft is a tectonic shift away from traditional rectangular shape cervical grafts. The trapezoidal shape is tremendous improvement in respecting the correct anatomy of patients," says Dr.Chokshi at Pee Dee Spine Center, Florence, SC.
The Latitude-C™ Cervical Interbody fusion devices come in variety of shapes and sizes:
- 5 different footprints from 12x12mm to 20x15mm and each size has 10 heights - 5 to 14mm
- There are 3 different shape options to choose from – Anatomic, Lordotic and Parallel
- The system is delivered in several color coded options for procedural flexibility
The Latitude-C™ interbody fusion devices will be available in Q1 of 2016.
About DeGen Medical, Inc.
DeGen Medical, Inc. is a medical-device development company dedicated to providing surgeons with innovative products engineered to improve quality of life for patients with complex spinal disorders. World-class implants, coupled with intuitively-designed instrumentation, provide a complete package to promote superior surgical outcomes. Our passion to advance spine-care solutions is driven by clinical insights, sound research, and science-based design. DeGen Medical maintains the highest quality standards to provide reliable products and safeguard patient health.
A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=38239
CONTACT: Jessica Clark
DeGen Medical, Inc.
Phone: 877-240-7838
www.DeGenmedical.com


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



